Singh Priti, Karkhur Samendra, Verma Vidhya
Ophthalmology, All India Institute of Medical Sciences, Bhopal, Bhopal, IND.
Cureus. 2025 Feb 17;17(2):e79160. doi: 10.7759/cureus.79160. eCollection 2025 Feb.
The present study aims to determine the incidences of ethambutol-induced optic neuropathy (EON) and its associated risk factors in Central Indian tertiary care centers.
A single-centered retrospective observational study was conducted. Data was collected from the Directly Observed Therapy Short-course (DOTS) centre after the revised National Tuberculosis Control Program (RNTCP) 2016 guidelines were implemented. The collected data included demographic data, history of underlying diseases, such as diabetes mellitus, hypertension, HIV infection, and history of smoking. The site of tuberculosis infection, daily dose, the duration of ethambutol (EMB) treatment, onset, and type of ocular symptoms were recorded. We performed regression analyses to investigate the univariate and multivariable associations with different variables.
Of the 1676 patients who received ethambutol for TB treatment, 987 had an ophthalmological symptom unrelated to EON, and 13 developed EON (incidence =0.28%). Demographic and clinical variables considered were age, gender, race/ethnicity, body mass index (BMI), and diabetes mellitus status. Examples of current infection information were chronic HIV and other comorbidities uniquely associated with renal function site/type treatment specific dose/duration ethambutol. Longer treatment duration significantly correlates with greater thickness of the left temporal retinal nerve fibre layer (RNFL) and thicker average RNFL. Increased peripapillary retinal nerve fibre layer (pRNFL) thickness on the left nasal RNFL scan was significantly correlated with ethambutol tablets (or count) (p=0.027).
The findings indicate that ethambutol toxicity is indeed dose and duration-dependent, evidenced by the relationship between prolonged treatment and increased RNFL thickness, suggesting heightened risk of visual impairment. Moreover, adverse effects were observed at even lower doses (12.3 mg/kg), reinforcing that no dose of ethambutol is entirely safe.
本研究旨在确定印度中部三级医疗中心乙胺丁醇所致视神经病变(EON)的发生率及其相关危险因素。
开展了一项单中心回顾性观察研究。在2016年修订的国家结核病控制规划(RNTCP)指南实施后,从直接观察短程治疗(DOTS)中心收集数据。收集的数据包括人口统计学数据、基础疾病史,如糖尿病、高血压、HIV感染以及吸烟史。记录结核感染部位、每日剂量、乙胺丁醇(EMB)治疗持续时间、眼部症状的发作情况和类型。我们进行了回归分析,以研究不同变量的单变量和多变量关联。
在1676例接受乙胺丁醇治疗结核病的患者中,987例有与EON无关的眼科症状,13例发生EON(发生率=0.28%)。所考虑的人口统计学和临床变量包括年龄、性别、种族/民族、体重指数(BMI)和糖尿病状态。当前感染信息的示例包括慢性HIV以及其他与肾功能部位/类型治疗特定剂量/持续时间乙胺丁醇独特相关的合并症。较长的治疗持续时间与左侧颞侧视网膜神经纤维层(RNFL)厚度增加以及平均RNFL增厚显著相关。左侧鼻侧RNFL扫描中视乳头周围视网膜神经纤维层(pRNFL)厚度增加与乙胺丁醇片(或数量)显著相关(p=0.027)。
研究结果表明,乙胺丁醇毒性确实与剂量和持续时间有关,长期治疗与RNFL厚度增加之间的关系证明了这一点,提示视力损害风险增加。此外,即使在较低剂量(12.3mg/kg)时也观察到了不良反应,这进一步证明没有剂量的乙胺丁醇是完全安全的。